ECErnest G. Chan

Ernest G. Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ernest G. Chan has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predicting Primary Graft Dysfunction in Systemic Sclerosis Lung Transplantation Using Machine‐Learning and CT Features

    by Jatin Singh, Xin Meng, Joseph K. Leader, John Ryan, Lucas Pu, Rachel Deitz, Ernest G. Chan, Norihisa Shigemura, Chadi A. Hage, Pablo G. Sanchez, et al.

    Introduction: Primary graft dysfunction (PGD) is a significant barrier to survival in lung transplant (LTx) recipients. PGD in patients with systemic sclerosis (SSc) remains especially underrepresented in research.Methods: We investigated 92 SSc recipients (mean age 51 years ± 10) who underwent bilateral LTx between 2007 and 2020. PGD was defined as grade 3 PGD at 72 h post‐LTx. A comprehensive set of CT image features was automatically computed from recipient chest CT scans using deep learning algorithms. Volumetric analysis of recipients’ lungs and chest cavity was used to estimate lung‐size matching. Four machine learning (ML) algorithms were developed to predict PGD, including multivariate logistic regression, support vector machine (SVM), random forest classifier (RFC), and multilayer perceptron (MLP).Results: PGD was significantly associated with BMI >30 kg/m2 (p = 0.009), African American race (p = 0.011), lower Preop FEV1 (p = 0.002) and FVC (p = 0.004), longer waitlist time (p = 0.014), higher lung allocation score (LAS) (p = 0.028), and interstitial lung disease (p = 0.050). From CT analysis, PGD was significantly associated with decreased lung volume (p < 0.001), increased heart‐chest cavity volume ratio (p < 0.001), epicardial (p = 0.033) and total heart (p = 0.049) adipose tissue, and five cardiopulmonary features (p < 0.050). Oversized donor allografts estimated using CT analysis were significantly associated with PGD (p < 0.050). The MLP model achieved a maximum AUROC of 0.85 (95% CI: 0.81–0.88) in predicting PGD with four features: Preop FEV1, heart‐chest cavity volume ratio, waitlist time, and donor to recipient chest cavity volume ratio.Conclusion: CT‐derived features are significantly associated with PGD, and models incorporating these features can predict PGD in SSc recipients.


  • Comparison of Robot-Assisted Versus Video-Assisted Thoracoscopic Segmentectomy: A Single-Institution Propensity-Matched Study

    by Kojo Agyabeng-Dadzie, Inderpal S. Sarkaria, Ernest Chan, Ian Christie, Summer Mazur, Kristine Ruppert, Neil Christie, Omar Awais, Ryan Levy, Nicholas Baker, et al.

    Objective: Previous studies have evaluated the feasibility of robot-assisted thoracoscopic segmentectomy (RVATS) in comparison with video-assisted thoracoscopic segmentectomy (VATS). We report both short-term and long-term outcomes comparing RVATS and VATS at a single institution. Methods: This is a retrospective propensity-matched cohort study reviewing RVATS and VATS for primary non-small cell lung cancer (NSCLC) performed from 2013 to 2021 at our institution; 1:2 propensity matching was performed. Results: There were 108 patients who underwent RVATS and 370 who underwent VATS for primary lung cancer. After propensity matching, we had 2 well-matched cohorts of 102 patients in the RVATS group and 204 in the VATS group. Our data showed no significant difference in 90-day mortality, 30-day hospital readmission rate, or median number of lymph nodes between the RVATS and VATS groups. There was also no significant difference in postoperative morbidity except for pleural effusion. RVATS had a significantly greater median number of lymph node stations harvested and longer operative time. Although both groups achieved R0 resections in all patients, RVATS showed a greater negative tumor margin distance compared with VATS. There was no significant difference in disease-free survival or overall survival between the 2 groups at 3 years. Conclusions: In our experience, RVATS showed a greater number of lymph node stations harvested and greater negative tumor margin distance without compromising perioperative and oncological outcomes for segmentectomy performed for NSCLC.


  • Assessment, Procurement, and Preservation of the Lungs

    by Takashi Harano, Ernest G. Chan, Pablo G. Sanchez

  • Lung transplantation after ex vivo lung perfusion in high-risk recipients: A propensity-score matched analysis of a national database

    by Ernest G. Chan, Rachel L. Deitz, Jack K. Donohue, John P. Ryan, Yota Suzuki, Masashi Furukawa, Kentaro Noda, Pablo G. Sanchez


  • Bloodless lung transplantation: Comparison between 2 central venoarterial extracorporeal membrane oxygenation anticoagulation strategies and their impact on lung transplant outcomes

    by Ernest G. Chan, Rachel L. Deitz, John P. Ryan, Yota Suzuki, Chadi A. Hage, Masashi Furukawa, Kentaro Noda, Kathirvel Subramaniam, Pablo G. Sanchez


  • Risk Factors and Outcomes Associated With the Development of Persistent Acute Kidney Injury in Non‐Renal Solid Organ Transplant Recipients: Systematic Review and Meta‐Analysis

    by Ivan E. Saraiva, Natsumi Hamahata, Ankit Sakhuja, Xinlei Chen, John S. Minturn, Pablo G. Sanchez, Ernest G. Chan, David J. Kaczorowski, Ali Al‐Khafaji, John A. Kellum, et al.

    Persistent acute kidney injury (pAKI), compared with acute kidney injury (AKI) that resolves in 2. We identified 25 studies including 6330 patients. AKI (8%–71.6%) and pAKI (2.7%–55.1%) varied widely. Definitions of pAKI included 48–72 h (six studies), 7 days (three studies), 14 days (four studies), or more (12 studies). Risk factors included age, body mass index (BMI), diabetes, preoperative chronic kidney disease (CKD), intraoperative vasopressor use, and intraoperative circulatory support. pAKI was associated with new onset of CKD (odds ratio [OR] 1.41–11.2), graft dysfunction (OR 1.81–8.51), and long‐term mortality (OR 3.01–13.96), although significant heterogeneity limited certainty of CKD and graft dysfunction outcome analyses. pAKI is common and is associated with worse mortality among liver and lung transplant recipients. Standardization of the nomenclature of AKI will be important in future studies (PROSPERO CRD42022371952).


  • Open Access

    Performance status at the time of lung retransplant predicts long‐term function

    by Rachel L. Deitz, Sarah Clifford, John P. Ryan, Ernest G. Chan, Jenalee N. Coster, Masashi Furukawa, Chadi A. Hage, Pablo G. Sanchez

    Background: Lung retransplantation is offered to select patients with chronic allograft dysfunction. Given the increased risk of morbidity and mortality conferred by retransplantation, post‐transplant function should be considered in the decision of who and when to list. The aim of this study is to identify predictors of post‐operative disability in patients undergoing lung retransplantation.Methods: Data were collected from the UNOS national dataset and included all patients who underwent lung retransplant from May 2005–March 2023. Pre‐ and post‐operative function was reported by the Karnofsky Performance Status (KPS) and patients were stratified based on their needs. Cumulative link mixed effects models identified associations between pre‐transplant variables and post‐transplant function.Results: A total of 1275 lung retransplant patients were included. After adjusting for between‐group differences, pre‐operative functional status was predictive of post‐transplant function; patients requiring Total Assistance ( n = 740) were 74% more likely than No/Some Assistance patients (n = 535) to require more assistance in follow‐up (OR 1.74, 95% CI 1.13–2.68, p = .012). Estimated one year survival of Total Assistance patients is lower than No/Some Assistance Recipients (72% vs. 82%, CI 69%–75%; 79%–86%) but similar to overall re‐transplant survival (76%, CI 74%–79%).Conclusion: Both survival and regain of function in patients requiring Total Assistance prior to retransplant may be higher than previously reported. Pre‐operative functional status is predictive of post‐operative function and should weigh in the selection, timing and post‐operative care of patients considered for lung retransplantation.

  • Lung transplantation in HIV seropositive recipients: An analysis of the UNOS registry

    by Jack K. Donohue, Ernest G. Chan, Sarah Clifford, John P. Ryan, Masashi Furukawa, Ghady Haidar, Alessandro Bertani, Chadi A. Hage, Pablo G. Sanchez

    Background: Experience with lung transplantation (LT) in patients with human immunodeficiency virus (HIV) is limited. Many studies have demonstrated the success of kidney and liver transplantation in HIV‐seropositive (HIV+) patients. Our objective was to conduct a national registry analysis comparing LT outcomes in HIV+ to HIV‐seronegative (HIV−) recipients.Methods: The United Network for Organ Sharing database was queried to identify LTs performed in adult HIV+ patients between 2016 and 2023. Patients with unknown HIV status, multiorgan transplants, and redo transplants were excluded. The primary endpoints were mortality and graft rejection. Survival time was analyzed using Kaplan–Meier analysis.Results: The study included 17 487 patients, 67 of whom were HIV+. HIV+ recipients were younger (59 vs. 62 years, p = .02), had higher pulmonary arterial pressure (28 vs. 25 mm Hg, p = .04), and higher lung allocation scores (47 vs. 41, p = .01) relative to HIV− recipients. There were no differences in graft/recipient survival time between groups. HIV+ recipients had higher rates of post‐transplant dialysis (18% vs. 8.4%, p = .01), but otherwise had similar post‐transplant outcomes to HIV‐recipients.Conclusions: This national registry analysis suggests LT outcomes in HIV+ patients are not inferior to outcomes in HIV− patients and that well‐selected HIV+ recipients can achieve comparable patient and graft survival rates relative to HIV− recipients.


  • Open Access

    Immediate Postoperative COVID-19 Infection after Lung Transplantation: A Systematic Review and Case Series

    by Jack K. Donohue, Eric J. Hyzny, Sarah Clifford, Ernest G. Chan, Jenalee Nicole Coster, Masashi Furukawa, Pablo G. Sanchez

    Background: With new variants challenging the effectiveness of preventive measures, we are beginning to recognize the reality that COVID-19 will continue to pose an endemic threat. The manifestations of COVID-19 in lung transplant recipients during index admission are poorly understood with very few cases reported in recent lung transplant recipients. Optimal management of immunosuppression and antiviral therapy in recent transplant recipients is challenging. Methods: We performed a retrospective analysis identifying lung transplant recipients at our institution who contracted COVID-19 in the immediate postoperative period (within index admission). In addition, we performed a systematic review from January 2020 to August 2023 identifying all publications on the PUBMED database regarding COVID-19 infection in lung transplant recipients during index admission. Results: We report four cases of COVID-19 pneumonia in lung transplant recipients in the immediate postoperative period and we describe the clinical course, treatment options, and immunosuppression changes to manage this unique clinical problem. All patients made a full recovery and were eventually discharged home. Within our review of the literature, the most prevalent presenting symptoms were cough, dyspnea, and fatigue. Six (75%) patients decreased or held their antimetabolite. The two most common treatments were monoclonal antibodies (38%) and remdesivir (63%). Conclusion: Although previous literature demonstrates that COVID-19 can be deadly in recent lung transplant recipients, rapid treatment with anti-viral therapy/immunotherapy, deescalating immunosuppression, and treatment of respiratory decompensation with Decadron was effective in our patients.


  • A novel scoring system to predict survival in cirrhotic patients undergoing isolated lung transplantation: The PENS‐CEPT score

    by Eric J. Hyzny, Ernest G. Chan, Chadi Hage, Vikrant Rachakonda, Pablo G. Sanchez, Shahid M. Malik

    Cirrhosis is usually regarded as a contraindication to isolated lung transplantation (ILT). We sought to determine which patients with cirrhosis could safely undergo ILT. Based on a retrospective analysis of patients with cirrhosis who underwent ILT at our center between 2007 and 2020, we developed an exclusionary algorithm (PENS‐CEPT: Pittsburgh ExclusioN Score in Cirrhotics Evaluated for Pulmonary Transplant) to help determine which patients can undergo ILT with minimal incurred risk from their underlying liver disease. The score utilizes a combination of readily available clinical data and the presence (or absence) of spontaneous portosystemic shunts on preoperative cross‐sectional imaging. Sixteen patients underwent ILT with a diagnosis of cirrhosis: nine with cystic fibrosis. On univariate analysis, only our model was able to predict 1 year survival. Of the nine patients that would have been approved using our model, there was only one short term death. Of the seven patients that would have been rejected by the model, all but one died within the first year with six dying of complications from liver failure. We are proposing a simple score utilizing routine clinical parameters and pre‐operative imaging to determine the safety of ILT in cirrhotic patients. Further studies are required to validate this scoring system with the goal of safely increasing the opportunity for cirrhotic patients who would otherwise be rejected for ILT.